ArticleJournal of translational medicine2025
PGC-1α mediates hypoxia-preconditioned olfactory mucosa mesenchymal stem cells improved neuroinflammatory response via inhibiting microglial ferroptosis in ischemic stroke.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of digital health interventions for adults with tuberculosis: a network meta-analysis of randomized controlled trials.Frontiers in medicine · 2026Pooled it
- Iron, Copper, and Zinc Dyshomeostasis in Cardiovascular and Cerebrovascular Diseases: Redox Mechanisms, Evidence Levels, and Translational Prospects.International journal of molecular sciences · 2026Review
- Organelle regulation of ferroptosis after intracerebral hemorrhage.Redox biology · 2026Review
- Resveratrol attenuates pyroptosis and neuroinflammation by inhibiting the TLR4/NF-κB/AIM2 pathway in ischemic stroke rats.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCerebral ischemia/reperfusion injury can induce nerve cell apoptosis and ferroptosis and activation of the neuroinflammatory cascade plays a critical role in ischemic stroke progression. Mesenchymal stem cells (MSCs) can aid in repairing nerve injuries and regulating inflammatory responses, but their roles in ischemic stroke are unknown.
methodsHere, we investigate the impact of microglial susceptibility to ferroptosis on neuronal apoptosis using an oxygen-glucose deprivation/reperfusion (OGD/R) model. Furthermore, we examined the effects of hypoxia-preconditioned olfactory mucosa mesenchymal stem cells (hOM-MSCs) on attenuating microglial ferroptosis and improving neuroinflammatory response in models of OGD/R and middle cerebral artery occlusion (MCAO).
resultsFirstly, it has been confirmed that the susceptibility of microglial to ferroptosis significantly amplifies their neuroinflammatory response, thereby accelerating neuronal apoptosis in the OGD/R model. A functional assay identified that the core functional factor, peroxisome proliferator-activated receptor-γ co-activator-1α (PGC-1α), secreted from hOM-MSCs has a critical role in the hOM-MSC-modulated recovery of cellular activity in neurons. This discovery was accomplished through inhibiting microglia ferroptosis and the enhancement of immune regulation in the area affected by an infarct, all of which are closely linked to neuroinflammatory reactions. Mechanistically, exposure to hOM-MSCs partially mediates the amelioration of neuroinflammatory response and restoration of neural function in ischemic stroke by means of PGC-1α activation within the infarct region, via initiation of the PPARα-GPX4/ACSL4-NFκB signaling cascades in microglia.
conclusionsThese findings provide convincing proof that PGC-1α plays a crucial role in facilitating the advantageous impacts of hOM-MSCs on the enhancement of neural functionality following an ischemic stroke. The treatment of hOM-MSC could be a promising and effective neuroprotective candidate to ischemic stroke, and PGC-1α may be used in isolation or in combination with hOM-MSCs for ischemic stroke treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.